| Serglycin: at the crossroad of inflammation and malignancy A Korpetinou, SS Skandalis, VT Labropoulou, G Smirlaki, A Noulas, ... Frontiers in oncology 3, 327, 2014 | 179 | 2014 |
| Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro AD Theocharis, C Seidel, M Borset, K Dobra, V Baykov, V Labropoulou, ... Journal of Biological Chemistry 281 (46), 35116-35128, 2006 | 120 | 2006 |
| Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells A Korpetinou, SS Skandalis, A Moustakas, KE Happonen, H Tveit, ... PloS one 8 (10), e78157, 2013 | 79 | 2013 |
| Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma A Skliris, KE Happonen, E Terpos, V Labropoulou, M Børset, D Heinegård, ... European journal of immunology 41 (2), 437-449, 2011 | 71 | 2011 |
| Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast … SS Skandalis, VT Labropoulou, P Ravazoula, E Likaki-Karatza, K Dobra, ... BMC cancer 11 (1), 314, 2011 | 65 | 2011 |
| Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group E Katodritou, E Terpos, S Delimpasi, M Kotsopoulou, E Michalis, ... Blood cancer journal 8 (3), 31, 2018 | 61 | 2018 |
| Cell‐surface serglycin promotes adhesion of myeloma cells to collagen type I and affects the expression of matrix metalloproteinases A Skliris, VT Labropoulou, DJ Papachristou, A Aletras, NK Karamanos, ... The FEBS journal 280 (10), 2342-2352, 2013 | 59 | 2013 |
| Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumours VT Labropoulou, AD Theocharis, P Ravazoula, P Perimenis, A Hjerpe, ... Histopathology 49 (6), 582-593, 2006 | 56 | 2006 |
| The incidence of myelodysplastic syndromes in Western Greece is increasing C Avgerinou, Y Alamanos, P Zikos, P Lampropoulou, M Melachrinou, ... Annals of hematology 92 (7), 877-887, 2013 | 49 | 2013 |
| Increased expression of serglycin in specific carcinomas and aggressive cancer cell lines A Korpetinou, DJ Papachristou, A Lampropoulou, P Bouris, ... BioMed research international 2015 (1), 690721, 2015 | 41 | 2015 |
| Imbalance of MMP‐2 and MMP‐9 expression versus TIMP‐1 and TIMP‐2 reflects increased invasiveness of human testicular germ cell tumours E Milia‐Argeiti, E Huet, VT Labropoulou, S Mourah, P Fenichel, ... International journal of andrology 35 (6), 835-844, 2012 | 34 | 2012 |
| Expression of syndecan‐4 and correlation with metastatic potential in testicular germ cell tumours VT Labropoulou, SS Skandalis, P Ravazoula, P Perimenis, ... BioMed Research International 2013 (1), 214864, 2013 | 33 | 2013 |
| Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: a multicenter study by the Greek myeloma study group E Katodritou, E Kastritis, D Dalampira, S Delimpasi, E Spanoudakis, ... American Journal of Hematology 98 (5), 730-738, 2023 | 31 | 2023 |
| Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study Group E Katodritou, D Dalampira, S Delimpasi, I Ntanasis‐Stathopoulos, ... American Journal of Hematology 99 (10), 1897-1905, 2024 | 16 | 2024 |
| Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study E Kastritis, E Terpos, A Symeonidis, V Labropoulou, S Delimpasi, ... American journal of hematology 98 (9), E226-E229, 2023 | 16 | 2023 |
| The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines I Kritikou, E Giannopoulou, AK Koutras, VT Labropoulou, HP Kalofonos Pharmaceutical biology 52 (4), 444-452, 2014 | 15 | 2014 |
| Pathophysiology and pharmacological targeting of tumor-induced bone disease: current status and emerging therapeutic interventions VT Labropoulou, AD Theocharis, A Symeonidis, SS Skandalis, ... Current medicinal chemistry 18 (11), 1584-1598, 2011 | 12 | 2011 |
| Choroidal thickness evaluation in a transfusion-dependent beta-thalassemia Greek population F Tsapardoni, OE Makri, V Lazaris, V Labropoulou, S Lygeros, ... Clinical Ophthalmology, 4511-4518, 2020 | 10 | 2020 |
| High Frequency of Post-Transfusion Microchimerism Among Multi-Transfused Beta-Thalassemic Patients S Matsagos, E Verigou, A Kourakli, S Alexis, S Vrakas, C Argyropoulou, ... Frontiers in Medicine 9, 845490, 2022 | 8 | 2022 |
| A multicenter cross-sectional study of the quality of life and iron chelation treatment satisfaction of patients with transfusion-dependent β-thalassemia, in routine care … V Goulas, A Kouraklis-Symeonidis, K Manousou, V Lazaris, G Pairas, ... Quality of Life Research 30 (2), 467-477, 2021 | 8 | 2021 |
Argiris SymeonidisUniversity of Patras, GreeceVerified email at upatras.gr
